Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Encapsulated placebo Clear all
Terminated Phase 4 Interventional Results available

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

NCT04547985
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Naltrexone HCl 50 MG Oral Tablet, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

NCT01730053
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Rosuvastatin, Ezetimibe, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
54
States / cities
Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 16, 2026, 6:36 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

NCT04102501
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
RT001, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
12 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 1 Interventional

Midodrine Hydrochloride in Early Sepsis

NCT03129542
View directory record Official record
Conditions
Sepsis, Blood Pressure
Interventions
Midodrine Hydrochloride 10 milligrams, Placebo capsule
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

NCT05639894
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization
Interventions
RSV vaccine candidate, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
25
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

NCT00705003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

NCT01955161
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

NCT03621657
View directory record Official record
Conditions
Clostridium Difficile Infection, C.Difficile Diarrhea, CDI
Interventions
Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 16, 2026, 6:36 AM EDT
Active, not recruiting Phase 3 Interventional

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

NCT03150914
View directory record Official record
Conditions
LAM, Lymphangioleiomyomatosis
Interventions
Sirolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 16, 2026, 6:36 AM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

NCT01515007
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 16, 2026, 6:36 AM EDT
Active, not recruiting Phase 2 Interventional

Effects of Simvastatin on Uterine Leiomyoma Size

NCT03400826
View directory record Official record
Conditions
Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Interventions
Simvastatin 40mg, Placebo 40 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 1 Interventional

Study of the Fecal Microbiome in Patients With Parkinson's Disease

NCT03671785
View directory record Official record
Conditions
Parkinson Disease
Interventions
PRIM-DJ2727, Placebo oral capsule
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
55 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 16, 2026, 6:36 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

NCT06123026
View directory record Official record
Conditions
Lactation Suppressed, Second Trimester Abortion
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

NCT00744016
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Granulated mesalamine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bristol, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
View directory record Official record
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 4 Interventional Results available

Effect of Perioperative Gabapentin on Postoperative Opioid Requirements

NCT05494385
View directory record Official record
Conditions
Postoperative Pain
Interventions
Preoperative Gabapentin/Postoperative Placebo, Preoperative Gabapentin/Postoperative Gabapentin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

NCT03431974
View directory record Official record
Conditions
Psoriasis
Interventions
LD-Aminopterin oral capsule, Placebo oral capsule
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Seattle, Washington • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 16, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

Neural Substrates in Nicotine Withdrawal

NCT01001520
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 16, 2026, 6:36 AM EDT